What's in The Cooper Health System's pipeline?

The Cooper Health System has 17 drugs in our index: 12 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with The Cooper Health System's portfolio?

Top competitors by shared drug class: Huazhong University of Science and Technology, The Cleveland Clinic, Bristol-Myers Squibb, Celltrion, Centocor, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/the-cooper-health-system.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

The Cooper Health System — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Cooper Health System pipeline: 12 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 0 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Northera	Northera	marketed		Muscarinic acetylcholine receptor M1, Adrenergic receptor	Neuroscience
Bupivacaine Injectable Solution	Bupivacaine Injectable Solution	marketed
Tylenol, Ibuprofen, and Oxycodone	Tylenol, Ibuprofen, and Oxycodone	marketed
IV opioid administration	IV opioid administration	marketed
Chlorhexidine gluconate (4%)	Chlorhexidine gluconate (4%)	marketed	Antimicrobial agent / Antiseptic		Infectious Disease / Antisepsis
Tylenol and Ibuprofen only	Tylenol and Ibuprofen only	marketed	Analgesic/Antipyretic combination (acetaminophen + NSAID)	Prostaglandin synthesis pathway; COX-1 and COX-2 enzymes	Pain Management
Remifentanil and Desflurane	Remifentanil and Desflurane	marketed	Opioid agonist and volatile anesthetic combination	Mu-opioid receptor (remifentanil); GABA receptors and ion channels (desflurane)	Anesthesia
Bezlotoxumab Injection	Bezlotoxumab Injection	marketed	Monoclonal antibody (toxin-neutralizing)	Clostridioides difficile toxin B	Infectious Disease
Dexemedetomidine	Dexemedetomidine	marketed			Other
Exparel Injectable Solution	Exparel Injectable Solution	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels	Pain Management / Anesthesia
Remifentanil, Dexmedetomidine, and Desflurane	Remifentanil, Dexmedetomidine, and Desflurane	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane)	Anesthesiology
Remifentanil, Propofol, and Desflurane	Remifentanil, Propofol, and Desflurane	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)	Anesthesiology

Therapeutic area mix

Anesthesiology · 2
Infectious Disease · 1
Infectious Disease / Antisepsis · 1
Neuroscience · 1
Oncology · 1
Other · 1
Pain Management · 1
Anesthesia · 1
Pain Management / Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Huazhong University of Science and Technology · 2 shared drug classes
The Cleveland Clinic · 2 shared drug classes
Bristol-Myers Squibb · 1 shared drug class
Celltrion · 1 shared drug class
Centocor, Inc. · 1 shared drug class
Clinique des Céphalées de Montréal · 1 shared drug class
Dermira, Inc. · 1 shared drug class
Catherine Vandepitte, M.D. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The Cooper Health System:

Cite this brief

Drug Landscape (2026). The Cooper Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-cooper-health-system. Accessed 2026-05-16.